Latest Regulatory Approvals News

Core Energy Minerals Ltd has struck a binding deal to acquire the Itambe Rare Earth Project from Rio Tinto, unlocking a district-scale opportunity in Brazil with soil assays revealing rare earth oxide concentrations exceeding 5,000ppm.

Olympio Metals has agreed to sell its Dufay Project in Quebec to Fokus Mining for CAD$500,000, streamlining its portfolio to concentrate on the promising Bousquet Gold Project near major gold mines.

Rox Resources secures ASX waiver allowing a discounted Share Purchase Plan without shareholder approval, enabling eligible investors to buy shares at $0.35 each. This move streamlines capital raising while limiting dilution to around 2.5%.

TPC Consolidated’s proposed acquisition by Wollar Holding Ltd hits a regulatory snag as FIRB approval misses the November 28 sunset deadline, casting uncertainty over the deal’s future.

Terra Critical Minerals has inked a binding deal to acquire the True American Tungsten Project in Nevada, a high-grade, historically productive site, while launching a $600,000 entitlement offer to fund exploration amid record tungsten prices.

Lynch Group Holdings Limited (LGL) will be suspended from ASX trading following Federal Court approval of its acquisition by Darwin Aus Bidco Pty Ltd. This marks a significant step in the company’s transition under new ownership.

Conico Ltd has appointed a new external auditor and secured shareholder approval for a significant 1-for-8 share consolidation at its 2025 Annual General Meeting.

MyState Limited has reached a pivotal merger milestone by consolidating Auswide Bank under its single banking licence, aiming to unlock significant cost synergies while maintaining customer continuity.

South Harz Potash Limited has taken a significant step beyond its German potash roots by securing an option to acquire the Glava Copper-Gold-Silver project in Sweden, marking the start of a diversified growth strategy into critical metals.

Renergen Limited and ASP Isotopes Inc. have secured crucial regulatory approvals and agreed to extend the deadline for completing their Scheme of Arrangement to January 2026, signaling steady progress in their strategic partnership.

TruScreen Group Limited reported a 17% decline in first half FY2026 product sales but affirmed full-year revenue guidance at NZ$2.8 million, supported by strategic expansions and a successful NZ$4 million capital raise.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.